Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic sclerosis
If a patient with limited scleroderma presents with the three active domains including skin thickening, inflammatory joint pain, and ILD would you consider starting Actemra?
Related Questions
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
How do you envision incorporating CAR-T therapy into your clinical practice?
How would you counsel a patient with systemic sclerosis who wants to consider microneedling on the face or other skin which is not clearly involved with scleroderma?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
How do you approach the significance of +RNP III antibody in a patient with positive ANA but no other signs or symptoms of systemic sclerosis?
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?
How do you approach symptom control in a patient with diffuse cutaneous systemic sclerosis (dcSSc) and rapidly progressive skin disease?
Would you consider altering immunosuppression in a patient with systemic sclerosis (already on systemic immunosuppression for interstitial lung disease) who has more recently been noted to have LV diastolic dysfunction with some reduction in EF in the absence of other worsening symptoms?
